RxDoctor Payments Data

Nora Zilber, MD

Internal Medicine · Brooklyn, NYNPI 1861413734

Payments from drug & device makers

$1,004in general payments, 2019–2025

Across 48 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$215
  • Merck$211
  • Pfizer$157
  • Lilly USA, LLC$111
  • GSK$99
  • AstraZeneca$61
  • plus $148 from 7 others

What the payments were for

  • Food & beverage$1,004100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,004 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$9,065
Medicare patients
45
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanumetSitagliptin Phos/Metformin Hcl73$91,768
FarxigaDapagliflozin Propanediol42$45,598
EliquisApixaban41$38,534
JanuviaSitagliptin Phosphate45$37,298
JardianceEmpagliflozin36$33,917
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$31,540
TradjentaLinagliptin29$26,138
CreonLipase/Protease/Amylase18$22,122
XareltoRivaroxaban19$18,388
LinzessLinaclotide12$18,223
VascepaIcosapent Ethyl46$17,531
Breo ElliptaFluticasone/Vilanterol30$11,493
Atorvastatin Calcium300$3,606
Nifedipine ErNifedipine114$3,256
Albuterol Sulfate HfaAlbuterol Sulfate110$3,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia$211$129,067118 claims
Boehringer IngelheimJardiance, Tradjenta$26$60,05465 claims
AstraZenecaFarxiga$61$45,59842 claims
GSKTrelegy Ellipta, Breo Ellipta$99$43,03372 claims
PfizerEliquis$157$38,53441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →